Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01772771|
Recruitment Status : Recruiting
First Posted : January 21, 2013
Last Update Posted : May 14, 2019
Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant.
The main goal of this study is to perform standardized testing of tumor tissue to learn which genes are mutated (have changed) to provide personalized cancer therapy options to patients at MD Anderson. Your doctor may be able to use testing information on your tumor to identify clinical trials that may be most relevant to you.
Another goal of this laboratory research study is to learn how often different genes mutate in patients with different cancers. Researchers will also use the information learned from this study to develop a database of the different kinds of mutations in cancer-related genes.
Researchers also hope to better understand how mutations in cancer-related genes may affect a patient's response to different therapies. Researchers can use this information to select specific therapies for future patients that are more likely to be effective.
This is an investigational study.
Up to 12,000 patients will take part in this study. All will be enrolled at MD Anderson.
|Condition or disease|
|Invasive Cancer Sarcoma Hematologic Cancer|
|Study Type :||Observational|
|Estimated Enrollment :||12000 participants|
|Official Title:||Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program|
|Actual Study Start Date :||March 2012|
|Estimated Primary Completion Date :||March 2032|
|Estimated Study Completion Date :||March 2033|
Patients with histologically or cytologically documented invasive cancer, sarcoma, or hematologic cancer
- Database of Somatic Mutations and Clinical Characteristics [ Time Frame: 20 years ]Collection and storage of tumor tissue specimens, blood and/or saliva samples of patients with cancer for somatic mutation analysis for assessing patients that may be eligible for new targeted therapy trials.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01772771
|Contact: Funda Meric-Bernstam, MDemail@example.com|
|United States, Texas|
|University of Texas MD Anderson Cancer Center/Regional Cancer Centers||Recruiting|
|Houston, Texas, United States, 77030|
|Principal Investigator: Funda Meric-Bernstam, MD|
|Study Chair:||Funda Meric-Bernstam, MD||M.D. Anderson Cancer Center|